Interim Report 2026
Filed with HKEX · Stock code 1099 · · 83 pages · English
The Company was established in January 2003 and listed on The Stock Exchange of Hong Kong Limited (stock code: 01099. HK) in September 2009, is a core subsidiary of China National Pharmaceutical Group Co., Ltd. and a top-rank distributor and retailer of pharmaceuticals, medical devices and healthcare products, and a leading supply-chain service provider in the PRC. The Group is mainly engaged in p
Sinopharm Group Co., Ltd. on 6ix
Earlier from Sinopharm
- Announcement (1) poll results of the extraordinary general meeting held on Tuesday, 15 September 2026; and (2) election of chairman and vice chairman of the board, and chairmen and members of the special committees of the board
- Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials
Later from Sinopharm
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Notice of board meeting
- An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
- Announcement principal unaudited accounting data and financial indicators of sinopharm (cncm ltd) for the third quarter of 2026
- Announcement preliminary financial data of sinopharm accord for the nine months ended 30 September 2026
Follow Sinopharm into a list and get an email when it puts out news.
Follow Sinopharm